#### 1 Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG

#### 2 antibody assay system detecting both N and S proteins in Japan

- 3 Rin Yokoyama<sup>1</sup>, Makoto Kurano<sup>1,2\*</sup>, Yoshifumi Morita<sup>1</sup>, Takuya Shimura<sup>1</sup>, Yuki Nakano<sup>1</sup>,
- 4 Chungen Qian<sup>3</sup>, Fuzhen Xia<sup>4</sup>, Fan He<sup>4</sup>, Yoshiro Kishi<sup>5</sup>, Jun Okada<sup>5</sup>, Naoyuki Yoshikawa<sup>1</sup>,
- 5 Yutaka Nagura<sup>6</sup>, Hitoshi Okazaki<sup>6</sup>, Kyoji Moriya<sup>7</sup>, Yasuyuki Seto<sup>8</sup>, Tatsuhiko Kodama<sup>9</sup>, and

- <sup>1</sup>Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan
- <sup>8</sup> <sup>2</sup>Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of

9 Tokyo, Tokyo, Ja	apan
--------------------	------

- <sup>10</sup> <sup>3</sup>The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for
- 11 Optoelectronics Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems
- 12 Biology Theme, Department of Biomedical Engineering, College of Life Science and
- 13 Technology, Huazhong University of Science and Technology, Hubei, P.R. China
- <sup>4</sup>Reagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, P.R. China
- <sup>15</sup> <sup>5</sup>Business Planning Department, Sales & Marketing Division, Medical & Biological
- 16 Laboratories Co., Ltd, Tokyo, Japan
- <sup>6</sup>Department of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan

<sup>6</sup> Yutaka Yatomi<sup>1,2\*</sup>

- <sup>18</sup> <sup>7</sup>Department of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan
- 19 <sup>8</sup>Department of Gastrointestinal Surgery, The University of Tokyo, Japan
- <sup>20</sup> <sup>9</sup>Laboratory for Systems Biology and Medicine, The University of Tokyo, Tokyo, Japan
- 21
- 22 \*Corresponding author
- 23 E-mail: kurano-tky@umin.ac.jp (M.K.) and yatoyuta-tky@umin.ac.jp (Y.Y.)
- 24 Running Title: Anti-SARS-CoV-2 IgM and IgG tests in Japan

#### 25 Address correspondence to:

- 26 Makoto Kurano, MD, PhD and Yutaka Yatomi, MD, PhD
- 27 Department of Clinical Laboratory Medicine, Graduate School of Medicine,
- 28 The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
- 29 Tel: +81-3-3815-5411;
- 30 Fax: +81-3-5689-0495;
- 31 e-mail: kurano-tky@umin.ac.jp (M.K.), yatoyuta-tky@umin.ac.jp (Y.Y)
- 32
- 33

34 Abbreviations: AU, arbitrary unit; CLIA, chemiluminescence immunoassay; CC	VID-19,
---	---------

- 35 coronavirus disease 2019; CV, coefficient variation; dsDNA, double-strand DNA; FDA, the
- 36 Food and Drug Administration; IgG, immunoglobulin G; IgM, immunoglobulin M; M2,
- 37 mitochondrial M2; N protein, Nucleocapsid protein; P-ANCA, myeloperoxidase antineutrophil
- 38 cytoplasmic antibody; RF, rheumatoid factor; RLU, relative light units; SARS-CoV-2, severe
- 39 acute respiratory syndrome coronavirus 2; SD, standard division; S protein, Spike protein; SS-A,
- 40 Sjögren's syndrome A

41

## 42 Abstract

43	PCR methods are presently the standard for the diagnosis of Coronavirus disease 2019
44	(COVID-19), but additional methodologies are needed to complement PCR methods, which
45	have some limitations. Here, we validated and investigated the usefulness of measuring serum
46	antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the
47	iFlash3000 CLIA analyzer. We measured IgM and IgG titers against SARS-CoV-2 in sera
48	collected from 26 PCR-positive COVID-19 patients, 53 COVID-19-suspected but
49	PCR-negative patients, and 20 and 100 randomly selected non-COVID-19 patients who visited
50	our hospital in 2020 and 2017, respectively. The within-day and between-day precisions were
51	regarded as good, since the coefficient variations were below 5%. Linearity was also considered
52	good between 0.6 AU/mL and 112.7 AU/mL for SARS-CoV-2 IgM and between 3.2 AU/mL and
53	55.3 AU/mL for SARS-CoV-2 IgG, while the linearity curves plateaued above the upper
54	measurement range. We also confirmed that the seroconversion and no-antibody titers were over
55	the cutoff values in all 100 serum samples collected in 2017. These results indicate that this
56	measurement system successfully detects SARS-CoV-2 IgM/IgG. We observed four
57	false-positive cases in the IgM assay and no false-positive cases in the IgG assay when 111
58	serum samples known to contain autoantibodies were evaluated. The concordance rates of the
59	antibody test with the PCR test were 98.1% for SARS-CoV-2 IgM and 100% for IgG among

- 60 PCR-negative cases and 30.8% for SARS-CoV-2 IgM and 73.1% for SARS-CoV-2 IgG among
- 61 PCR-positive cases. In conclusion, the performance of this measurement system is sufficient for
- 62 use in laboratory testing.

63

## 64 Introduction

65	In December 2019, the first pneumonia cases caused by an unknown microorganism
66	were identified in Wuhan, China.[1] The pathogen was identified as a novel betacoronavirus and
67	was named "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." [2]
68	SARS-CoV-2 is phylogenetically similar to SARS-CoV, which caused outbreaks of a severe
69	respiratory syndrome in China in 2002.[3] The symptoms of coronavirus disease 2019
70	(COVID-19), which is the respiratory syndrome caused by SARS-CoV-2, are fever, cough and
71	lymphopenia.[4] Chest computed tomography examinations of COVID-19 patients are
72	characterized by the bilateral distribution of patchy shadows or ground-glass opacities.[5] Since
73	early December 2019 and as of June 15, 2020, over 7,800,000 cases of COVID-19 have been
74	confirmed and 430,000 deaths have been reported throughout the world,[6] and the World
75	Health Organization has reported a fatality rate for cases defined as pneumonia of
76	approximately 2%.[7]

Currently, COVID-19 is diagnosed by the clinical presentation of the patient, as described above, and the detection of SARS-CoV-2 RNA in respiratory specimens, such as a nasal swab or sputum, using real-time reverse-transcription polymerase chain reaction (RT-PCR).[8,9] However, this method requires skilled technicians who know how to handle genetic samples and perform PCR tests and occasionally causes false-negative results because

82 of the viral replication window, a low viral titer, or incorrect sample collection.[10] Moreover,
83 the sampling of respiratory specimens exposes medical staff to a higher risk of secondary
84 infection through aerosolization than the sampling of sera.[11,12] Therefore, other methods are
85 required to complement PCR testing.

86 Candidate complementary tests include both antigen and antibody tests. Regarding 87 antigen tests, although this method does not require special skills for performing genetic testing, 88 there remains a high risk of secondary infection during sampling, and the sensitivity of antigen 89 tests is reportedly lower than that of PCR testing.[13,14] Antibody tests are another candidate. 90 Compared with PCR testing, this serological test method has a faster turn-around time and 91requires easier and safer sample collection and less specialized skills for technicians; 92furthermore, when we interpret the results of an antibody testing considering the duration after 93 the onset of COVID-19, this test would give us important information in diagnosing COVID-19. 94The main concern regarding antibody tests is the high frequency of false-positive cases, which 95is a parameter that should depend on the quality of the test product. [15,16] Recently, Shenzhen 96 YHLO Biotech Co., Ltd (China) has developed an antibody test with a high specificity[17–19]; 97however, this method has not yet been validated in the Japanese population. Therefore, in the 98 present study, we aimed to validate the measurement of IgM and IgG antibodies against 99 SARS-CoV-2 in sera and to investigate the usefulness of this method for the diagnosis of

100 COVID-19.

101

### **Materials and Methods**

#### 103 **Subjects**

104We enrolled a total of 26 COVID-19-positive cases and 53 COVID-29-suspected cases 105who were hospitalized at The University of Tokyo Hospital. Confirmed COVID-19 cases were 106 defined based on the guidelines of The University of Tokyo Hospital. Briefly, patients with 107acute respiratory infection syndrome accompanied by detectable SARS-CoV-2 RNA in a throat 108swab or sputum at least once were confirmed as having COVID-19 (PCR-positive cases). 109Suspected patients were defined as subjects with respiratory symptoms, a history of overseas 110travel, or a high-risk contact with a confirmed COVID-19 case but with negative PCR results. 111 We collected residual sera available after routine clinical testing and kept it frozen until 112measurement. The serological tests were performed using the sample that had been collected on 113the day closest to the day on which the sample for the PCR test had been collected. As control 114groups, we randomly selected 20 and 100 outpatients who had visited The University of Tokyo 115Hospital in March 2020 or January-December 2017, respectively. We also corrected 111 serum 116samples known to contain autoantibodies.

117 The current study was performed in accordance with the Declaration of Helsinki. 118 Informed consent was obtained in the form of an opt-out form on the institution's website. This 119 study was conducted with the approval of The University of Tokyo Medical Research Center 120 Ethics Committee (2019300NI-3).

### 121 Antibody testing

122	Antibody testing was performed using SARS-CoV-2 IgM and IgG chemiluminescence
123	immunoassay (CLIA) kits supplied by Shenzhen YHLO Biotech Co., Ltd. (China) and an
124	iFlash3000 fully automated CLIA analyzer also from Shenzhen YHLO Biotech Co., Ltd.
125	(China). Two antigens of SARS-CoV-2 (nucleocapsid protein [N protein] and spike protein [S
126	protein]) were coated on the magnetic beads of these CLIA assays. The SARS-CoV-2 IgM or
127	IgG titers were calculated as relative light units (RLU) obtained from the analyzer and were
128	described as arbitrary units per milliliter (AU/mL). According to the manufacturer's instructions,
129	the cutoff value for a positive SARS-CoV-2 IgM/IgG result was deemed as 10 AU/mL. If the
130	SARS-CoV-2 IgG titer was over 40 AU/mL, the sample was diluted with non-reactive serum
131	and the antibody titers were measured once again.

### 132 Method validation

133 The within-day precision was validated by measuring 3 kinds of serum samples with

134	20 replications simultaneously. Then, we calculated the mean value, the standard deviation (SD),
135	and the coefficient of variation (CV) for each sample. The between-day precision was validated
136	using two kinds of quality-control samples provided by the manufacturer. These samples were
137	measured twice a day on days 0, 1, 2, 3, 4, 5, 9-11, and 16. Linearity was investigated using two
138	kinds of pooled serum samples. Briefly, each sample was diluted with pooled non-reactive
139	serum in two-fold serial dilutions for ten times. To investigate the existence of the prozone
140	phenomenon, we diluted the samples with high concentrations of SARS-CoV-2 IgM and IgG
141	titers using ten-fold serial dilutions for the SARS-CoV-2 IgM assay and two-fold serial dilutions
142	for the SARS-CoV-2 IgG assay.

### 143 Statistical analysis

The data were analyzed using StatFlex software (Osaka, Japan). The results were expressed as the mean  $\pm$  SD. The Dunn test was used for comparisons of antibody titers between the control and other groups. A value of p < 0.05 was regarded as statistically significant in all the analyses.

148

# 149 **Results**

### 150 Precision and accuracy of antibody testing

151	First, we investigated the precision and accuracy of the antibody testing. As shown in
152	Table 1A, the intra-day precision values were 1.9%-2.9% for SARS-CoV-2 IgM and 1.1%-3.3%
153	for SARS-CoV-2 IgG, while the between-day precision values were 1.9%-3.3% for
154	SARS-CoV-2 IgM and 2.5%-3.7% for SARS-CoV-2 IgG.

155

### 156 Table 1. Within-day and between-day precision of SARS-CoV-2 IgM/IgG titers

A. Within-day precision				
	Sample	Mean (AU/mL)	SD (AU/mL)	CV (%)
SARS-CoV-2 IgM	1	2.0	0.04	2.03
	2	7.0	0.13	1.86
	3	83.8	2.46	2.94
SARS-CoV-2 IgG	4	3.7	0.06	1.68
	5	10.2	0.11	1.06
	6	74.3	2.47	3.32
B. Between-day precision				
	Sample	Mean (AU/mL)	SD (AU/mL)	CV (%)
SARS-CoV-2 IgM	1	3.8	0.13	3.31
	2	15.9	0.30	1.90
SARS-CoV-2 IgG	3	5.1	0.13	2.53

4	17.5	0.64	3.67
-			

- 157 (A)Within-day precision. We measured SARS-CoV-2 IgM and IgG in three kinds of samples;
- 158 each sample was the analyzed with 20 replicates on the same day. (B) Between-day precision.
- 159 We continuously measured two kinds of samples on days 0, 1, 2, 3, 4, 5, 9-11, and 16; each
- 160 sample was analyzed with 2 replicates.
- 161

#### 162 Measurement range of SARS-CoV-2 antibody testing

163	To explore the measurement range of this antibody test, we performed a linear
164	regression analysis. When we investigated linearity using samples with moderate antibody titers,
165	the curves showed a good linearity between 0.6 AU/mL and 112.7 AU/mL for SARS-CoV-2 $$
166	IgM and between 3.2 AU/mL and 55.3 AU/mL for SARS-CoV-2 IgG (Fig. 1). Next, we
167	measured samples with high antibody titers to determine the upper limit of the measurement
168	range. In the SARS-CoV-2 IgM assay, the upper curve increased up to a value of 2,405 AU/mL
169	and then reached a plateau at higher concentrations. In the SARS-CoV-2 IgG assay, the curve
170	reached a plateau at values over 73 AU/mL (Fig. 2). Therefore, we diluted the samples and
171	determined the SARS-CoV-2 IgG titers for SARS-CoV-2 IgG levels over 50 AU/mL. In both
172	assays, a hook effect was not observed.

#### 174 Fig 1. Linearity analyses of SARS-CoV-2 antibody titer.

- 175 The dilution linearities of SARS-CoV-2 IgM (A, B) and SARS-CoV-2 IgG (C, D) were
- 176 investigated. A sample was diluted with non-reactive serum in 5 to 8 steps; each sample was
- 177 then analyzed with two replicates.
- 178

#### 179 Fig 2. Prozone phenomena of SARS-CoV-2 antibody titer.

- 180 The prozone phenomena of SARS-CoV-2 IgM (A) and SARS-CoV-2 IgG (B) were investigated.
- 181 We diluted two serum samples from infected patients with non-reactive serum in 10 steps; each
- 182 sample was then analyzed with two replicates.
- 183

#### 184 Successful detection of SARS-CoV-2 IgM/IgG

To confirm that this antibody measurement system could detect SARS-CoV-2 IgM/IgG successfully, we measured the antibody titers in sera obtained before and after infection with SARS-CoV-2 in three cases of COVID-19 confirmed using RT-PCR tests. As shown in Fig. 3, SARS-CoV-2 IgM and IgG were not detected before symptom onset; at several days after symptom onset, tests for both antibodies became positive and the titers gradually increased. In case 1, the IgM test once again became negative 19 days after hospitalization.

- 192 visited The University of Tokyo Hospital in 2017, when SARS-CoV-2 did not exist. None of
- 193 these samples had an antibody titer over 10 AU/mL, suggesting that this measurement system
- 194 can detect SARS-CoV-2 IgM/IgG without false-positive results (Fig. 4).

195

- 196 Fig 3. Time course of serum antibody titers in COVID-19 subjects.
- 197 The time courses of the SARS-CoV-2 IgM and SARS-CoV-2 IgG titers in sera collected before
- and after the onset of COVID-19 were examined in three patients.
- 199
- 200 Fig 4. Serum antibody titers in sera from 2017.
- 201 The SARS-CoV-2 IgM/IgG titers of sera collected from subjects (n = 100) in 2017 were
- 202 measured.
- 203

#### 204 **Cross-reactivity with autoantibodies**

205 Since the presence of autoantibodies can sometimes affect the results of serological 206 tests, we measured SARS-CoV-2 IgM/IgG in residual serum samples collected from patients

207	with one of 5 different autoimmune diseases. For IgM, most of the serum samples from the
208	patients with autoimmune diseases did not have a result over 10 AU/mL. However, two
209	rheumatoid factor-positive patients, one anti-double-strand DNA antibody-positive patient, and
210	one anti-mitochondrial M2 antibody-positive patient had values that exceeded the cutoff value
211	(Fig. 5A). For IgG, none of the autoantibody-positive serum samples had a result that was over
212	10 AU/mL (Fig. 5B).

213

### Fig 5. Interference from autoantibodies in SARS-CoV-2 IgM/IgG assay.

215	We collected sera from patients with autoimmune diseases and measured the SARS-CoV-2 IgM
216	(A) and IgG (B) titers. $*p < 0.05$ , $**p < 0.01$ . Control, randomly selected outpatients who
217	visited the hospital in 2020 (n = 20); RF, rheumatoid factor-positive group (n = 25); dsDNA,
218	anti-double-strand DNA antibody-positive group (n = 26); M2, anti-mitochondrial M2
219	antibody-positive group (n = 20); P-ANCA, myeloperoxidase antineutrophil cytoplasmic
220	antibody-positive group (n = 20); SS-A, anti-Sjögren's syndrome A antibody-positive group (n =
221	20); Suspected, suspected COVID-19 group ( $n = 53$ ); Positive, COVID-19-positive group ( $n = 53$ ); Positive group ( $n = 53$ ]; Positive group ( $n = 53$ ]; Positive group ( $n = 53$ ]; Positive grou
222	26).

223

#### 224 **Concordance rate with PCR testing**

225	To investigate clinical usefulness, we compared the results of the serological antibody
226	tests with those of PCR tests. Among the 26 PCR-positive COVID-19 cases, 8 cases (30.8%)
227	had IgM-positive results and 19 cases (73.1%) had IgG-positive results. Among the 53
228	PCR-negative COVID-19-suspected cases, 52 cases (98.1%) had IgM levels below 10 AU/mL $$
229	and all the cases (100%) had IgG levels below 10 AU/mL (Table 2).
230	
231	Table 2. Concordance rate between the results of PCR testing and SARS-CoV-2 IgM or
232	IgG serological testing
	SARS-CoV-2 PCR test
	positive cases (n = negative cases (n =
	26) 53)

 SARS-CoV-2 IgM
 >10 AU/mL
 8 (30.8%)
 1

 ≤10 AU/mL
 18
 52 (98.1%)

 SARS-CoV-2 PCR test

positive cases (n = negative cases (n =

		26)	53)
SARS-CoV-2 IgG	>10 AU/mL	19 (73.1%)	0
	$\leq 10 \text{ AU/mL}$	7	53 (100%)

233 We measured SARS-CoV-2 IgM and IgG in PCR-positive subjects (n = 26) and PCR-negative

subjects (n = 53). An antibody titer above 10 AU/mL was regarded as positive, according to the

235 manufacturer's cutoff.

236

### 237 Suspected false-positive IgM results might be caused by reactivity to N protein

- In this study, we observed 5 suspected false-positive IgM results. As described in the *Materials and Methods* section, the measurement system tests the reactivity to both the N protein and the S protein of SARS-CoV-2. We investigated the reactivity of the samples to N protein and S protein separately, and only reactivity to N protein was observed in the 5 suspected false-positive samples (Table 3).
- 243

#### Table 3. IgM reactivity to N protein and S protein in subjects with suspected false-negative

245 **IgM results** 

	Sample	S+N protein (AU/mL)	N protein (AU/mL)	S protein (AU/mL)
--	--------	---------------------	-------------------	-------------------

1	53.76	97.17	0.34
2	16.43	18.14	0.96
3	13.03	10.51	0.34
4	17.94	29.31	0.69
5	110.11	130.57	1.15

We investigated the IgM reactivity to N protein and S protein in five subjects with suspected false-negative IgM results. N or S protein means the value measured using magnetic beads coated with either antigen, respectively.

249

# 250 **Discussion**

251	In this study, we validated a method for quantifying SARS-CoV-2 IgM and IgG using
252	the iFlash3000 automated CLIA analyzer. First, the within-day precisions of the SARS-CoV-2
253	IgM and IgG assays were obviously good in validations using three kinds of serum samples: a
254	sample with a negative antibody titer, a sample with a titer close to the cutoff level, and an
255	obviously positive sample (Table 1A). The between-day precisions for both assays also seemed
256	good (Table 1B). These results suggest that relatively stable data were provided by this
257	measurement system, while some anti-SARS-CoV-2 antibody detection kits authorized for
258	emergency use by the Food and Drug Administration (FDA) in the USA have a CV of more than

259	5% for within-day precision and some manufacturers do not even publish precision data for
260	their products. The linearity was good up to values of 112.7 AU/mL for SARS-CoV-2 IgM and
261	55.3 AU/mL for IgG, while the assay signal gradually reached a plateau at over 2,405 AU/mL
262	for SARS-CoV-2 IgM and over 73 AU/mL for IgG (Fig. 2). Therefore, the sample should be
263	diluted if the measured value is expected to be higher than the measurement range. To dilute
264	samples, non-reactive serum should be used as a diluent, since the titers are calculated as values
265	lower than the actual values when saline is used as a diluent, especially for IgM measurements
266	(data not shown). Clinical decisions are rarely affected by this phenomenon, since the
267	measurement range that was validated in the present study covers much higher values than the
268	manufacturer's cutoff.

269Regarding the antibody tests, in addition to issues surrounding accuracy, the matter of 270false-positive cases has also been a concern. As shown in Fig. 3, the SARS-CoV-2 IgM/IgG 271levels were negative before hospitalization in three cases, and these antibody levels 272subsequently became positive after symptom onset in all cases, suggesting that this serological 273test can surely detect antibodies against SARS-CoV-2. In addition, we demonstrated that this 274measurement system could detect SARS-CoV-2 IgM/IgG without any false-positive results by 275evaluating 100 serum samples collected in 2017, when SARS-CoV-2 did not exist. These results 276confirm that this measurement system might be able to detect antibodies against SARS-CoV-2

277	alone, without cross-reactivity with other coronavirus strains that cause 15%-29% of all
278	common colds.[20,21] Chemiluminescence immunoassays are known to be affected by
279	autoantibodies, such as rheumatoid factor, relatively often.[22] In the present study, we
280	investigated whether five kinds of autoantibodies might interfere with the measurement system
281	and found that no false-positive results were observed for the IgG assays, while four
282	false-positive cases were observed for the IgM assays. We also found one PCR-negative case
283	with a SARS-CoV-2 IgM titer over the cutoff value. Actually, when we investigated the
284	reactivity of N protein and S protein to the sera separately, we found that the false-positive cases
285	were caused by reactivity to the N protein (Table 3). The reason for this reactivity remains
286	unclear at present but might be due to the cross-reactivity of the measurement system or, since
287	the structure of the N protein of SARS-CoV-2 is similar to that of other coronavirus strains,
288	antibodies to a structure similar to the N protein of SARS-CoV-2 might actually exist.
289	Finally, we investigated the concordance rate between PCR and this measurement
290	system. As shown in Table 2, although all the PCR-negative subjects had negative results except
291	for one subject with a high IgM level, the PCR-positive subjects did not necessarily have

292 positive results for IgM or IgG. This discrepancy might be due to the fact that we used the 293 serum sample that had been collected on the day nearest to the day on which the PCR sample 294 had been collected. In several cases, only a few days had passed since the onset of symptoms,

and IgG and IgM are reportedly not detectable during the early phase of COVID-19.[23]
Therefore, the time course for the appearance of IgG and IgM must be investigated for the
application of antibody tests in clinical practice.

298A characteristic of the present method is that both the N protein and the S protein are 299used as antigens. Reportedly, the sensitivity and specificity might depend on the types of 300 antigens that are recognized by the antibodies, and the antibody to S protein is more sensitive 301 than the antibody to N protein.[24–26] Since the measurement system in the present study uses 302 both the S and N proteins, this system might provide a greater sensitivity and diagnostic ability 303 than an antibody test using either the S protein or the N protein alone. In contrast, analyzing the 304 reactivity to both proteins could increase the number of false-positive cases, as described above. 305 Further studies on the clinical significances of antibodies to N protein and S protein might be 306 necessary to conclude which is most appropriate: measuring the reactivity to both proteins or to 307 each protein separately.

In conclusion, we have validated a measurement system for detecting IgM and IgG against SARS-CoV-2 using CLIA kits and have observed that this system had sufficient performance for its introduction into clinical laboratory testing. Moreover, the possibility of false-negative results, especially for IgG against SARS-CoV-2, was relatively low. In the future, this method might be helpful for clinical diagnosis, epidemiological investigations, and the

313 development of vaccines.

314

### 315 Acknowledgements

316 We are thankful to the Murakami Foundation for the donation of the iFlash3000 to The

317 University of Tokyo Hospital.

318

### **Funding Sources**

320 None.

321

### **322** Authorship Contributions

323 R.Y. participated in experiments and the data analysis and drafted the initial manuscript, Y.N.,

324 Y.M., T.S., Y.N., and N.Y. participated in the experiments. M.K. participated in the study design,

- data analysis, helped to draft the manuscript, and conceived the study. C.Q., F. X., F. H., Y. K.
- and J. O. developed the antibody measurement system. H.O., K.M., and Y.S. participated in the
- 327 discussion and helped to draft the manuscript. T.K. and Y.Y. conceived the study, coordinated
- 328 the study design, and helped to draft the manuscript. All the authors have read and approved the

329 final manuscript.

330

### **Disclosure of Conflicts of Interest**

332 The present study is a collaborative research project among The University of Tokyo, Shenzhen

333 YHLO Biotech Co., Ltd, and Medical & Biological Laboratories Co., Ltd. F. X. and F. H. are

and the set of Shenzhen YHLO Biotech Co., Ltd and Y. K. and J. O. are employees of Medical

335 & Biological Laboratories Co., Ltd.

336

### **Data Availability Statement**

338 The datasets generated or analyzed in the current study are available upon reasonable

339 request.

340

## 341 **References**

- 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
- infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497–506.
- 344 doi:10.1016/S0140-6736(20)30183-5
- 2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and

346		epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
347		binding. Lancet. 2020;395: 565-574. doi:10.1016/S0140-6736(20)30251-8
348	3.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from
349		patients with pneumonia in China, 2019. N Engl J Med. 2020;382: 727-733.
350		doi:10.1056/NEJMoa2001017
351	4.	Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus
352		Disease 2019 in China. N Engl J Med. 2020;382: 1708–1720.
353		doi:10.1056/NEJMoa2002032
354	5.	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
355		Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
356		China. JAMA - J Am Med Assoc. 2020;323: 1061–1069. doi:10.1001/jama.2020.1585
357	6.	World Health Organization. Coronavirus disease (COVID-19) Situation Report-147.
358		Available from: https://apps.who.int/iris/handle/10665/332550
359	7.	World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-36.
360		Available from: https://apps.who.int/iris/handle/10665/331222
361	8.	World Health Organization. Laboratory testing for coronavirus disease 2019
362		(COVID-19) in suspected human cases: interim guidance, 2 March 2020. 2020.

363		Available from: https://apps.who.int/iris/handle/10665/331329
364	9.	Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
365		Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382:
366		1199–1207. doi:10.1056/NEJMoa2001316
367	10.	Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of
368		different respiratory specimens in the laboratory diagnosis and monitoring the viral
369		shedding of 2019-nCoV infections. medRxiv [Preprint]. Cold Spring Harbor Laboratory
370		Press; 2020. p. 2020.02.11.20021493. doi:10.1101/2020.02.11.20021493
371	11.	Kim J-M, Kim HM, Lee EJ, Jo HJ, Yoon Y, Lee N-J, et al. Detection and Isolation of
372		SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the
373		Republic of Korea. Osong Public Heal Res Perspect. 2020;11: 112–117.
374		doi:10.24171/j.phrp.2020.11.3.02
375	12.	Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
376		Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:
377		465–469. doi:10.1038/s41586-020-2196-x
378	13.	Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of
379		novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory

380		samples. Int J Infect Dis [Preprint]. 2020 [cited 28 Jun 2020].
381		doi:10.1016/j.ijid.2020.05.098
382	14.	Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A,
383		Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline
384		testing for COVID-19 diagnosis. J Clin Virol. 2020;129. doi:10.1016/j.jcv.2020.104455
385	15.	Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. A Method To Prevent SARS-CoV-2
386		IgM False Positives in Gold Immunochromatography and Enzyme-Linked
387		Immunosorbent Assays. J Clin Microbiol. 2020;58. doi:10.1128/JCM.00375-20
388	16.	Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of
389		A Rapid IgM $\Box$ IgG Combined Antibody Test for SARS $\Box$ CoV $\Box$ 2 Infection Diagnosis. J
390		Med Virol. 2020; jmv.25727. doi:10.1002/jmv.25727
391	17.	Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. Diagnostic
392		accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM
393		and IgG antibodies: an Italian experience. J Med Virol. 2020; 1-5.
394		doi:10.1002/jmv.25932
395	18.	Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of
396		SARS-CoV-2 from an Infected Mother to Her Newborn. JAMA - Journal of the

397		American Medical Association. American Medical Association; 2020. pp. 1846–1848.
398		doi:10.1001/jama.2020.4621
399	19.	Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to
400		Mothers with COVID-19 Pneumonia. JAMA - Journal of the American Medical
401		Association. American Medical Association; 2020. pp. 1848–1849.
402		doi:10.1001/jama.2020.4861
403	20.	Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic
404		Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology. Elsevier
405		Ltd; 2016. pp. 490–502. doi:10.1016/j.tim.2016.03.003
406	21.	Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med. 1974;47: 234–51.
407	22.	Hirano K, Maruyama S, Mino Y, Naito T, Kawakami J. Suitability of chemiluminescent
408		enzyme immunoassay for the measurement of blood tacrolimus concentrations in
409		rheumatoid arthritis. Clin Biochem. 2011;44: 397–402.
410		doi:10.1016/j.clinbiochem.2010.12.020
411	23.	Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance
412		of serum antibody in coronavirus disease 2019. Int J Infect Dis. 2020;94: 49–52.
413		doi:10.1016/j.ijid.2020.03.065

414	24.	Zhong L, Chuan J,	Gong B, Shuai P,	Zhou Y, Zhang	Y, et al. Dete	ection of serum IgM
-----	-----	-------------------	------------------	---------------	----------------	---------------------

- 415 and IgG for COVID-19 diagnosis. Sci China Life Sci. 2020;63: 777–780.
- 416 doi:10.1007/s11427-020-1688-9
- 417 25. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in
- 418 detecting SARS-CoV-2 infection: A meta-analysis. Diagnostics. 2020;10.
- 419 doi:10.3390/diagnostics10050319
- 420 26. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and
- 421 Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies
- 422 against SARS-CoV-2. J Clin Microbiol. 2020;58. doi:10.1128/JCM.00461-20

423









